DVA

DaVita

$161.03

+3.00%
Nov 20, 2026
Bobby Quantitative Model
DaVita Inc. is one of the largest kidney care providers in the United States, operating a network of more than 3,200 outpatient dialysis facilities worldwide and treating roughly 300,000 patients annually, with the bulk of revenue generated through US dialysis and related laboratory services reimbursed by government payers (primarily Medicare) and commercial insurers. The company holds approximately 35% US market share in a duopoly-like industry alongside Fresenius, giving it scale advantages in a capital-intensive, regulated, and reimbursement-sensitive business where commercial payers—though only about 10% of patients—generate nearly all US dialysis profits. The current investor narrative centers on the durability of that commercial mix against Medicare rate pressure, the growth of its integrated kidney care (IKC) value-based segment, and a Q3 2026 earnings beat that nonetheless came with cautious guidance and margin pressure commentary. Sentiment has been whipsawed by a sharp post-August de-rating tied to reimbursement and cost concerns, partially offset by aggressive share repurchases and a forward earnings multiple that screens cheap relative to the broader market.

People also watch

HCA Healthcare

HCA Healthcare

HCA

Analysis
Tenet Healthcare

Tenet Healthcare

THC

Analysis
Encompass Health

Encompass Health

EHC

Analysis
Universal Health Services

Universal Health Services

UHS

Analysis
The Ensign Group, Inc.

The Ensign Group, Inc.

ENSG

Analysis

BobbyInvestment Opinion: Should I buy DVA Today?

Rating: Hold with a constructive bias toward accumulation on stabilization. The core thesis is that DaVita's 9.24x forward PE against $18.12 consensus EPS, $1.29 billion of TTM free cash flow, and a 42.2% gap to the $222.29 average analyst target already discount much of the reimbursement and margin fear, but the 2.5 recommendation mean (3 Buy, 3 Hold, 2 Sell) and the accelerating downtrend (-21.25% over six months, -10.84% over one month) mean the market is demanding proof of margin stabilization before re-rating the equity. This is a valuation-and-cash-flow story awaiting a catalyst, not a momentum story.

The supporting evidence is unusually concrete for a stock this beaten down: forward PE of 9.24x versus a trailing 11.29x and a historical band of roughly 8.4x-24.6x, PS of 0.62x versus the 2.3x-4.2x range seen from 2021 through 2025, and EV/EBITDA of 8.60x all sit at or near multi-year lows for a business generating $1.294 billion of TTM free cash flow. Revenue grew 4.62% year-over-year to $3.578 billion in Q3 2026, net income rose 48% to $222.9 million (net margin 6.23% versus 4.40%), and the buyback cut share count from 86.1 million in Q4 2025 to 63.8 million in Q3 2026, mechanically lifting per-share earnings. Even the $165 analyst low target sits above the $156.34 price, implying the Street's most cautious model sees no further downside from here.

The risks that could invalidate the thesis are margin erosion, leverage, and payer concentration. Gross margin fell sequentially from 32.70% to 31.50% and EBITDA from $753.1 million to $673.9 million between Q2 and Q3 2026, while 3.33x interest coverage on $150.0 million of quarterly interest expense and negative book value (debt-to-equity of -23.12) leave no equity cushion for a reimbursement shock. This Hold would upgrade to Buy if gross margin stabilizes back above 32% and the stock reclaims the $188-$195 breakdown shelf, and would downgrade to Sell if gross margin slides toward 30% or forward EPS estimates fall below the $17.81 low. On balance the stock is undervalued relative to its own history and to healthcare facilities peers, but fairly-to-cheaply valued relative to a genuinely uncertain reimbursement trajectory—a discount that is earned, not free.

Sign up to view all

DVA 12-Month Price Forecast

DaVita presents a classic value-versus-momentum standoff: the valuation is objectively cheap at 9.24x forward earnings and 0.62x sales for a business generating $1.29 billion of free cash flow, and even the $165 analyst low target sits above the $156.34 price. But the evidence that matters most over the next two quarters is margin direction, and that evidence is currently negative—gross margin fell 120 basis points sequentially and EBITDA dropped $79 million, which is exactly why the stock has de-rated 21.25% over six months despite a still-positive 35.71% one-year return. The 42.2% gap to the $222.29 average target reflects how far the price has fallen below the Street's models rather than uniform bullishness, and the 3 Hold and 2 Sell ratings show analysts want proof before capitulating. I would upgrade to bullish on a reclaim of the $188-$195 breakdown shelf combined with gross margin back above 32%, and downgrade to bearish if gross margin approaches 30% or forward EPS estimates slip below $17.81. Until one of those resolves, the risk/reward favors patience over conviction.

Historical Price
Current Price $161.03
Average Target $161.03
High Target $185.18
Low Target $136.88

Wall Street consensus

Coverage is moderate with 7 analysts, split 3 Buy, 3 Hold, and 2 Sell—a genuinely divided consensus that yields a recommendation mean of 2.5 and an aggregate "buy" label that masks significant disagreement. The average target price of $222.29 implies roughly +42.2% upside from the current $156.34, a wide gap that reflects how far the stock has fallen below where the Street's models sit rather than uniform bullishness. The recent institutional actions show a mixed tape: TD Cowen upgraded to Buy from Hold in August 2026 and reiterated Buy in November, UBS has stayed Buy throughout, while Barclays remains Equal Weight and Truist holds a Hold—suggesting analysts are not rushing to capitulate despite the price collapse.

The target range of $165.00 to $287.00 is exceptionally wide—a $122 spread, or roughly 78% of the current share price—signaling high uncertainty about the reimbursement and margin trajectory. The $287 high target likely assumes IKC value-based care scaling, stable commercial payer mix, multiple expansion back toward historical norms, and continued aggressive buyback accretion against consensus EPS of $18.12; the $165 low target, notably still above the current $156.34, prices in margin compression, Medicare rate pressure, and leverage constraints without assuming a full breakdown. That even the bear case sits above the market price suggests the selloff may have overshot, but the 3 Hold and 2 Sell ratings and the absence of any recent upgrades below $200 indicate the Street wants evidence of margin stabilization before turning constructive.

Drowning in data?

Find the real signal!

Bulls vs Bears: DVA Investment Factors

The bear case currently has stronger near-term evidence: the stock is in an accelerating downtrend (-10.84% in one month, -21.25% in six months), margins compressed sequentially in Q3, and the Street is genuinely split at a 2.5 recommendation mean with two Sells. The bull case rests on valuation and cash generation—9.24x forward earnings, 0.62x sales, $1.29 billion of free cash flow, and a 42.2% gap to the $222.29 average target—which is compelling but has been compelling for months while the price kept falling. The single most important tension is whether the Q3 margin compression is a transient cost blip or the start of structural reimbursement erosion; if gross margin stabilizes back above 32%, the valuation case likely wins, but a further slide toward 30% would validate the Sells and put the $101 low in play. Until the tape shows a reversal—ideally a reclaim of the $188-$195 breakdown shelf—the evidence favors caution over conviction.

Bullish

  • Forward PE of 9.24x is deeply discounted: Against consensus FY EPS of $18.12, DVA trades at just 9.24x forward earnings versus a trailing PE of 11.29x and mid-to-high-teens multiples typical of profitable healthcare facilities peers. The PS ratio of 0.62x and EV/EBITDA of 8.60x corroborate a valuation near the bottom of the stock's own 8.4x-24.6x historical PE band.
  • Analyst targets imply 42% upside: The $222.29 average target sits 42.2% above the $156.34 price, and even the $165 low target is above the current quote, suggesting the Street's most cautious model still sees no further downside. TD Cowen upgraded to Buy in August 2026 and reiterated in November, while UBS has stayed Buy throughout the selloff.
  • Robust $1.29B free cash flow funds buybacks: TTM free cash flow of $1.294 billion comfortably covers $159.5 million of quarterly capex and funded $109.5 million of Q3 buybacks, with operating cash flow of $518.8 million in the quarter. Share count has fallen from 86.1 million (Q4 2025) to 63.8 million (Q3 2026), an aggressive repurchase program that mechanically lifts EPS.
  • Year-over-year profitability improved sharply: Q3 2026 net income of $222.9 million rose 48% from $150.3 million a year earlier, lifting net margin to 6.23% from 4.40%, while gross margin held at 31.50% and operating margin at 13.95%. Revenue also grew 4.62% year-over-year to $3.578 billion, extending a consistent $3.42B-$3.62B quarterly cadence.

Bearish

  • Momentum breakdown is severe and accelerating: The stock is down 21.25% over six months and 10.84% over the past month, closing at $156.34 after a -3.37% session, and sits only 22.1% of the way up its $101.00-$247.49 52-week range. The August gap-down from $227.99 to $188.69 marked a decisive re-rating, and relative strength versus SPY has deteriorated 17.26% over six months.
  • Sequential margin compression is real: Gross margin fell from 32.70% in Q2 to 31.50% in Q3, operating margin from 16.06% to 13.95%, and EBITDA from $753.1 million to $673.9 million quarter-over-quarter. Post-earnings commentary flagged cautious guidance and cost pressure, directly undercutting the thesis that reimbursement fears are overdone.
  • Thin 3.33x interest coverage on heavy debt: Quarterly interest expense of $150.0 million against $499.3 million of operating income leaves only 3.33x coverage, and negative book value (debt-to-equity of -23.12, P/B of -12.95) means leverage must be serviced entirely from cash flow. Any rise in refinancing costs or a Medicare rate cut would squeeze the equity disproportionately.
  • Commercial payer concentration drives all profit: Government payers account for roughly two-thirds of US sales but commercial insurers—only about 10% of patients—generate nearly all US dialysis profits. A shift in commercial mix, payer pressure, or Medicare rate policy therefore hits the earnings base far harder than the 4.62% revenue growth rate implies.

DVA Technical Analysis

DaVita is in a clear intermediate downtrend despite a still-positive 1-year return of +35.71%, a divergence that reflects a strong first half giving way to a sustained second-half slide. At $156.34, the stock sits just 22.1% of the way up its 52-week range of $101.00 to $247.49—only about $55 above the low and roughly $91 below the high—placing it deep in the lower quartile of its annual band, a positioning that signals momentum breakdown rather than a healthy pullback within an uptrend. The 6-month change of -21.25% versus the 1-year gain of +35.71% confirms the trend has rolled over decisively since the summer peak near $240.

Short-term momentum is unambiguously negative and accelerating to the downside: the 1-month change of -10.84% and 3-month change of -10.06% show persistent selling pressure, with the most recent session alone down -3.37% on a close of $156.34 versus the prior $161.79. This 1-month weakness directly conflicts with the +36.53% YTD gain, a classic divergence that typically signals either a violent mean-reversion correction of an overextended advance or the early stage of a fundamental re-rating—given the August gap-down from $227.99 to $188.69, the latter interpretation carries weight. Relative strength versus SPY has deteriorated sharply over the intermediate term (-17.26% over 6 months and -3.92% over 1 month) even as the 1-year relative strength remains +27.68%, underscoring how much of the outperformance has already been surrendered.

Key technical levels are well defined: support sits at the 52-week low of $101.00, with the recent $156-$174 zone acting as the immediate battleground, while resistance is anchored at the 52-week high of $247.49 and the $188-$195 shelf where the August breakdown originated. A decisive break below $156 would open the door toward the $140s and ultimately the $101 low, whereas reclaiming $188 would be the first credible sign of a trend repair. With a beta of 0.858, DaVita is roughly 14% less volatile than the market, which modestly cushions position sizing risk, but the -35.12% max drawdown and 6.9 short ratio indicate that liquidity and crowded short positioning can amplify moves in either direction.

Beta

—

—

Max Drawdown

-35.1%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

+39.6%

Cumulative gain past year

PeriodDVA ReturnS&P 500
1m-8.9%-9.7%
3m-7.4%-9.9%
6m-18.9%-7.5%
1y+39.6%+4.7%
ytd+40.6%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

DVA Fundamental Analysis

Revenue is growing steadily but at a modest pace: Q3 2026 revenue of $3.578 billion rose 4.62% year-over-year versus $3.420 billion in Q3 2025, extending a consistent multi-quarter cadence of roughly $3.42B to $3.62B per quarter across the trailing eight periods. The sequential progression from $3.416B (Q1 2026) to $3.554B (Q2) to $3.578B (Q3) shows low-single-digit expansion rather than acceleration, consistent with a mature, reimbursement-driven model where the US dialysis and related lab segment accounts for the overwhelming majority of the $10.12 billion disclosed segment revenue. The investment case therefore rests less on top-line growth and more on payer mix, IKC value-based contract economics, and capital return rather than volume-driven expansion.

Profitability is solid and improving on a year-over-year basis: Q3 2026 net income of $222.9 million compares favorably to $150.3 million in Q3 2025, lifting net margin to 6.23% from 4.40%, while gross margin of 31.50% and operating margin of 13.95% remain within the company's historical band. Sequentially, however, margins compressed from Q2's 32.70% gross and 16.06% operating levels, and EBITDA fell from $753.1 million to $673.9 million—evidence of the cost and reimbursement pressures flagged in post-earnings commentary. The 27.00% trailing gross margin and 14.74% operating margin in the valuation dataset confirm a business that is profitable but structurally margin-constrained by government rate-setting, with the negative ROE of -114.70% reflecting a deeply negative equity base rather than operating losses.

Balance sheet optics are distorted by an accumulated deficit that produces a negative book value, evidenced by debt-to-equity of -23.12 and a P/B of -12.95, so leverage must be assessed through cash flow instead. Free cash flow is robust at $1.294 billion TTM, with quarterly FCF of $359.3 million in Q3 2026 and operating cash flow of $518.8 million, comfortably covering $159.5 million of capex and funding $109.5 million of buybacks; the current ratio of 1.29 and interest coverage of 3.33x indicate adequate near-term liquidity against $150.0 million of quarterly interest expense. The company is clearly self-funding, but the thin 3.33x interest coverage and heavy debt load mean refinancing costs and rate sensitivity remain a genuine financial risk that constrains the equity's re-rating potential.

Quarterly Revenue

$3.6B

2026-09

Revenue YoY Growth

+4.6%

YoY Comparison

Gross Margin

31.5%

Latest Quarter

Free Cash Flow

$1.3B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

U S Dialysis And Related Lab Services

Open an Account, get $2 TSLA now!

Valuation Analysis: Is DVA Overvalued?

Because DaVita is profitable—Q3 2026 net income of $222.9 million and trailing EPS of $3.49—the PE ratio is the appropriate primary metric, and it paints a compelling picture: the trailing PE of 11.29x drops to a forward PE of just 9.24x against consensus FY EPS estimates of $18.12. That roughly 18% compression between trailing and forward multiples implies the market expects meaningful earnings growth, yet the stock is priced as though that growth is at risk, a disconnect that frames the central valuation debate. The PS ratio of 0.62x and EV/EBITDA of 8.60x further corroborate a low-multiple, cash-generative profile.

Relative to the healthcare facilities peer group, DaVita trades at a pronounced discount: a forward PE near 9.2x and EV/EBITDA of 8.6x sit well below the mid-to-high-teens multiples typical of profitable healthcare services operators, and the 0.62x sales multiple is exceptionally low for a business with $14+ billion in revenue and double-digit operating margins. This discount is only partially justified—the negative equity, 3.33x interest coverage, and Medicare reimbursement dependence are real structural handicaps—but a PEG of -1.30 (distorted by the negative equity-driven earnings base) and P/CF of 4.47x suggest the market is pricing in substantial pessimism relative to the company's $1.29 billion FCF generation.

Historically, DaVita's PE has ranged from roughly 8.4x to 24.6x over the past several years, with the current 11.29x trailing multiple sitting in the lower-middle portion of that band and the 9.24x forward figure near the low end. The PS ratio of 0.62x is dramatically below the 2.3x-4.2x range seen from 2021 through 2025, a compression that reflects both the post-selloff share price and the market's diminished growth expectations. Near the bottom of its own historical valuation band, the stock offers either a genuine value opportunity if reimbursement fears prove overdone, or a value trap if margin pressure and leverage continue to erode the earnings base.

PE

11.3x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 8x~19x

vs. Industry Avg

18.9x

Industry PE ~18.9x*

EV/EBITDA

8.6x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on leverage and margin durability. Interest expense of $150.0 million per quarter against $499.3 million of operating income yields only 3.33x coverage, and with negative book value (debt-to-equity of -23.12) there is no equity cushion to absorb a shock. Margins are already eroding sequentially—gross margin fell from 32.70% to 31.50% and EBITDA from $753.1 million to $673.9 million between Q2 and Q3 2026—and because commercial payers representing only ~10% of patients generate nearly all US dialysis profit, a modest mix shift or rate concession can move earnings far more than the 4.62% revenue growth suggests. The buyback that supports EPS ($109.5 million in Q3, share count down from 86.1 million to 63.8 million) also consumes cash that could otherwise de-lever. Market and competitive risks are dominated by valuation compression and reimbursement policy. Even after the selloff, the stock has de-rated from a $247.49 high to $156.34, and the 6-month relative strength versus SPY of -17.26% shows the market actively repricing the name rather than trading around it; a beta of 0.858 offers only modest insulation. The duopoly with Fresenius limits price competition but not regulatory risk—Medicare rate-setting, IKC value-based contract economics, and commercial payer negotiations are the swing factors, and the Q3 beat accompanied by cautious guidance is exactly the pattern that keeps multiples depressed. Sector rotation away from defensive healthcare services into higher-growth areas would compound the pressure, and the 6.9 short ratio means crowded bearish positioning can amplify downdrafts. The worst-case scenario is a reimbursement cut or commercial mix deterioration that pushes gross margin toward 30%, compressing forward EPS below the $17.81 low estimate and forcing the market to apply a low-end multiple to a shrinking earnings base. In that chain, the stock would retest the $101.00 52-week low, a decline of roughly -35% from $156.34, consistent with the -35.12% max drawdown already recorded. Even the analyst low target of $165 sits above the current price, so the realistic downside is defined by the 52-week low rather than the Street's bear case—investors should size positions assuming a one-third loss is possible if margin stabilization fails to materialize.

FAQ

Ranked by severity, the first risk is reimbursement and payer concentration: government payers supply about two-thirds of US sales but commercial insurers—only ~10% of patients—generate nearly all US dialysis profit, so a Medicare rate cut or commercial mix shift can move earnings far more than the 4.62% revenue growth implies. Second is margin erosion, already visible in the Q2-to-Q3 2026 slide from 32.70% to 31.50% gross margin and $753.1 million to $673.9 million EBITDA, which if it continues toward 30% would invalidate the forward EPS estimate. Third is leverage: $150.0 million of quarterly interest expense against $499.3 million of operating income gives just 3.33x coverage, and with negative book value there is no equity cushion if refinancing costs rise. Fourth is market and momentum risk—the stock is down 10.84% in one month and 21.25% in six months with relative strength versus SPY off 17.26% over six months, and a 6.9 short ratio means crowded bearish positioning can amplify further downdrafts toward the $101.00 low.

The 12-month forecast splits into three scenarios. The base case carries 50% probability with a $185-$222 range, assuming gross margin stabilizes in the low-31% range, revenue holds its 4.62% pace, and the stock grinds toward the $222.29 average analyst target without a full re-rating. The bull case at 25% probability targets $247-$287—the 52-week high of $247.49 and the $287 analyst high—requiring gross margin back above 32%, profitable IKC value-based scaling, and a broker upgrade cycle pulling the 2.5 recommendation mean toward 2.0. The bear case at 25% probability spans $101-$165, driven by a Medicare rate cut or commercial mix deterioration that pushes gross margin toward 30% and EPS below the $17.81 low, retesting the $101.00 52-week low. The base case is most likely because the $165 analyst low target already sits above the $156.34 price, implying limited further downside if estimates hold; the key assumption is that the Q3 margin compression is a transient cost blip rather than structural reimbursement erosion.

By most measures DVA screens undervalued. The trailing PE of 11.29x compresses to 9.24x forward against $18.12 of consensus EPS, placing it near the low end of its own roughly 8.4x-24.6x historical band, while the 0.62x PS ratio is far below the 2.3x-4.2x range seen from 2021 through 2025 and EV/EBITDA of 8.60x sits below mid-to-high-teens healthcare facilities peers. The P/CF of 4.47x and $1.294 billion of free cash flow reinforce that the market is pricing substantial pessimism. What the valuation implies is that investors expect margin compression and reimbursement pressure to persist—the forward multiple only looks cheap if the $18.12 EPS estimate holds, and the $17.81 low estimate marks the line in the sand. The discount is therefore partly earned rather than free: negative book value (debt-to-equity of -23.12) and 3.33x interest coverage justify some structural discount, but a 42.2% gap to the average target suggests the selloff has overshot relative to fundamentals.

The risk/reward is asymmetric but conditional. On the positive side, the stock at $156.34 trades at 9.24x consensus FY EPS of $18.12 and 0.62x sales, generates $1.294 billion of trailing free cash flow, and sits 42.2% below the $222.29 average analyst target—with even the $165 low target above the current price. On the negative side, gross margin fell from 32.70% to 31.50% and EBITDA from $753.1 million to $673.9 million sequentially in Q3 2026, interest coverage is only 3.33x on $150.0 million of quarterly interest expense, and the stock is down 21.25% over six months with a 2.5 recommendation mean split 3 Buy/3 Hold/2 Sell. The realistic downside is a retest of the $101.00 52-week low, roughly -35% from here. It is a good buy for value-oriented investors who can tolerate that drawdown and want to accumulate on evidence of margin stabilization; it is not a good buy for anyone who needs the downtrend to reverse first, since the tape has not confirmed a bottom.

DVA is better suited to a long-term, value-oriented holding than to short-term trading. The business is mature—revenue grows at 4.62% and quarterly sales have tracked a narrow $3.42B-$3.62B cadence—so returns depend on multiple normalization and buyback accretion rather than rapid expansion, which takes time; the share count already fell from 86.1 million to 63.8 million over four quarters. It pays no dividend (payout ratio of 0), so there is no income component and no yield support during drawdowns. Volatility is moderate on a beta basis at 0.858, but the -35.12% max drawdown, 6.9 short ratio, and 10.84% one-month decline show the downside can be sharp and fast, which argues against short-term positioning without a defined stop below $156. A concrete minimum holding period of 12-24 months is appropriate, giving at least two to three earnings cycles to confirm whether gross margin stabilizes above 32% and whether the $188-$195 breakdown shelf is reclaimed.